Literature DB >> 29681624

Rapid on-site evaluation during endoscopic ultrasound-guided fine-needle aspiration of lymph nodes does not increase diagnostic yield: A randomized, multicenter trial.

W F W Kappelle1, M E Van Leerdam1, M P Schwartz1, M Bülbül1, W A Buikhuisen1, M A Brink1, D M D S Sie-Go1, H J M Pullens1, S Nikolakopoulos1, P J Van Diest1, M Leenders1, L M G Moons1, A Bogte1, P D Siersema1,1, F P Vleggaar1.   

Abstract

OBJECTIVES: Studies on the impact of rapid on-site evaluation (ROSE) during endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of lymph nodes are retrospective and have shown conflicting results. We aimed to compare the diagnostic yield of EUS-FNA of lymph nodes with ROSE (ROSE+) and without ROSE (ROSE-).
METHODS: This was a multicenter, randomized controlled trial. Consecutive patients who were scheduled to undergo EUS-FNA of mediastinal or abdominal lymph nodes were randomized to ROSE+ or ROSE-. In the ROSE+ group, the number of passes was dictated by the on-site cytotechnician. In the ROSE- group, five passes were performed without interference from the cytotechnician. All samples were reviewed by a single-expert cytopathologist, blinded to group allocation. Primary endpoint was diagnostic yield with and without ROSE.
RESULTS: After inclusion of 90 patients, interim analysis showed futility of study continuation since diagnostic yield of ROSE+ and ROSE- were comparable. A total of 91 patients were randomized to ROSE+ (N = 45) or ROSE- (N = 46). Diagnostic yield of ROSE+ and ROSE- and diagnostic accuracy were comparable: 93.3% vs. 95.7% (P = 0.68) and 97.6% vs. 93.2% (P = 0.62), respectively. Two major complications (one per group) occurred (p = 0.99). ROSE- patients more often reported self-limiting post-procedural pain (p < 0.001). Median procedure time for ROSE+ (20 min) and ROSE- (23 min) was comparable (P = 0.06). Median time to review slides in the ROSE- group (12:47 min) was longer than with ROSE+ (7:52 min) (P < 0.001). Mean costs of ROSE- and ROSE+ were comparable: €938.29 (±172.70) vs. €945.98 (±223.38) (P = 0.91), respectively.
CONCLUSIONS: Diagnostic yield and accuracy of EUS-FNA of mediastinal and abdominal lymph nodes with and without ROSE are comparable. Time needed to review slides was shorter and post-procedural pain was less often reported in the ROSE+ group. Based on the primary outcome, the implementation of ROSE during EUS-FNA of mediastinal and abdominal lymph nodes cannot be advised. (Dutch Trial Register: NTR4876).

Entities:  

Mesh:

Year:  2018        PMID: 29681624     DOI: 10.1038/s41395-018-0025-8

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Motion-compensated FDG PET/CT for oesophageal cancer.

Authors:  Francine E M Voncken; Erik Vegt; Johanna W van Sandick; Jolanda M van Dieren; Cecile Grootscholten; Annemarieke Bartels-Rutten; Steven L Takken; Jan-Jakob Sonke; Jeroen B van de Kamer; Berthe M P Aleman
Journal:  Strahlenther Onkol       Date:  2021-04-07       Impact factor: 3.621

2.  Rapid on-site evaluation (ROSE) with EUS-FNA: The ROSE looks beautiful.

Authors:  Fei Yang; Enshuo Liu; Siyu Sun
Journal:  Endosc Ultrasound       Date:  2019 Sep-Oct       Impact factor: 5.628

3.  An international, multi-institution survey on performing EUS-FNA and fine needle biopsy.

Authors:  Jintao Guo; Anand V Sahai; Anthony Teoh; Paolo Giorgio Arcidiacono; Alberto Larghi; Adrian Saftoiu; Ali A Siddiqui; Brenda Lucia Arturo Arias; Christian Jenssen; Douglas G Adler; Sundeep Lakhtakia; Dong-Wan Seo; Fumihide Itokawa; Marc Giovannini; Girish Mishra; Luis Sabbagh; Atsushi Irisawa; Julio Iglesias-Garcia; Jan Werner Poley; Juan J Vila; Lachter Jesse; Kensuke Kubota; Evangelos Kalaitzakis; Mitsuhiro Kida; Mohamed El-Nady; Sh Untaro Mukai; Takeshi Ogura; Pietro Fusaroli; Peter Vilmann; Praveer Rai; Nam Q Nguyen; Ryan Ponnudurai; Chalapathi Rao Achanta; Todd H Baron; Ichiro Yasuda; Hsiu-Po Wang; Jinlong Hu; Bowen Duan; Manoop S Bhutani; Siyu Sun
Journal:  Endosc Ultrasound       Date:  2020 Sep-Oct       Impact factor: 5.628

4.  Macroscopic on-site evaluation after EUS-guided fine needle biopsy may replace rapid on-site evaluation.

Authors:  Hoonsub So; Dong-Wan Seo; Jun Seong Hwang; Sung Woo Ko; Dongwook Oh; Tae Jun Song; Do Hyun Park; Sung Koo Lee; Myung-Hwan Kim
Journal:  Endosc Ultrasound       Date:  2021 Mar-Apr       Impact factor: 5.628

5.  Predicting Malignancy of Biliary Stricture with a Nomogram in Patients with a Non-Malignant Endoscopic Tissue Diagnosis: A Retrospective Study.

Authors:  Yizhen Zhang; Qingwei Jiang; Qiang Wang; Yunlu Feng; Dongsheng Wu; Tao Guo; Shengyu Zhang; Xi Chen; Yingyun Yang; Wen Shi; Xi Wu; Aiming Yang
Journal:  Cancer Manag Res       Date:  2021-10-11       Impact factor: 3.989

Review 6.  Role of EBUS-TBNA in Non-Neoplastic Mediastinal Lymphadenopathy: Review of Literature.

Authors:  Valentina Scano; Alessandro Giuseppe Fois; Andrea Manca; Francesca Balata; Angelo Zinellu; Carla Chessa; Pietro Pirina; Panos Paliogiannis
Journal:  Diagnostics (Basel)       Date:  2022-02-16

7.  Macroscopic on-site evaluation (MOSE) of specimens from solid lesions acquired during EUS-FNB: multicenter study and comparison between needle gauges.

Authors:  Benedetto Mangiavillano; Leonardo Frazzoni; Thomas Togliani; Carlo Fabbri; Ilaria Tarantino; Luca De Luca; Teresa Staiano; Cecilia Binda; Marianna Signoretti; Leonardo H Eusebi; Francesco Auriemma; Laura Lamonaca; Danilo Paduano; Milena Di Leo; Silvia Carrara; Lorenzo Fuccio; Alessandro Repici
Journal:  Endosc Int Open       Date:  2021-05-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.